Edition:
United States

Proteon Therapeutics Inc (PRTO.OQ)

PRTO.OQ on NASDAQ Stock Exchange Global Market

2.61USD
18 Jan 2019
Change (% chg)

$0.01 (+0.38%)
Prev Close
$2.60
Open
$2.59
Day's High
$2.64
Day's Low
$2.59
Volume
980
Avg. Vol
11,387
52-wk High
$2.90
52-wk Low
$1.50

Latest Key Developments (Source: Significant Developments)

Proteon Therapeutics reports third quarter results
Wednesday, 7 Nov 2018 08:00am EST 

Nov 7 (Reuters) - Proteon Therapeutics Inc ::PROTEON THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.PROTEON THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS & AVAILABLE-FOR-SALE INVESTMENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO Q1 OF 2020.PROTEON THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE INVESTMENTS TOTALED $26.2 MILLION AS OF SEPTEMBER 30, 2018.PROTEON THERAPEUTICS INC - QTRLY NET LOSS PER SHARE $0.25.  Full Article

Proteon Therapeutics Posts Q2 Loss Per Share $0.28
Tuesday, 7 Aug 2018 08:00am EDT 

Aug 7 (Reuters) - Proteon Therapeutics Inc ::PROTEON THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.28.Q2 EARNINGS PER SHARE VIEW $-0.36 -- THOMSON REUTERS I/B/E/S.  Full Article

Proteon Therapeutics Q3 ‍loss per share $1.08​
Tuesday, 7 Nov 2017 08:00am EST 

Nov 7 (Reuters) - Proteon Therapeutics Inc :Proteon Therapeutics announces third quarter 2017 financial results.Remain on-track to complete enrollment in Q1 of 2018 in patency-2, co's second phase 3 clinical trial of vonapanitase​.Qtrly ‍loss per share $1.08​.Expects its cash, cash equivalents, available-for-sale investments will be sufficient to fund its operations into Q4 of 2019,.Q3 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.  Full Article